Clinical Trials Logo

Cannabis clinical trials

View clinical trials related to Cannabis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05436236 Withdrawn - Cannabis Clinical Trials

Effect of Cannabis (Marijuana) on Stomach Emptying Before Surgery

Start date: December 1, 2024
Phase:
Study type: Observational

The purpose of this research is to study the effect of cannabis (marijuana) on gastric (stomach) emptying before surgery. The study will include people who use cannabis (study group) and people who do not use cannabis (control group).

NCT ID: NCT04860089 Withdrawn - HIV Infections Clinical Trials

Pain, Inflammation, and Cannabis in HIV

PITCH-E
Start date: August 2022
Phase:
Study type: Observational

This study will examine how medical cannabis use affects neuropathic pain, inflammation and adverse events in people living with HIV (PLWH) with neuropathic pain. We will study how varying ratios of THC and CBD in medical cannabis impact neuropathic pain, inflammation and adverse events.

NCT ID: NCT03555968 Withdrawn - Alcohol Drinking Clinical Trials

Effects of THC and Alcohol on Driving Performance

Start date: July 2021
Phase: Phase 4
Study type: Interventional

Low blood concentrations of THC and alcohol appear to have a minimal effect on driving performance.However, there is a gap in the literature about the combined effects of THC and alcohol. There is little empirical evidence to determine whether the combination of THC and alcohol could be additive or multiplicative. This issue is particularly important when dealing with concentrations that are just below legal thresholds - it is important to identify if someone who may have consumed cannabis and alcohol, in quantities that do not exceed legal thresholds, may nonetheless be impaired to drive. Answering this question requires more research on the combined effects of THC and alcohol under tightly controlled experimental conditions. Hence, the purpose of this study is to determine the additive (or multiplicative) effect of standardized low doses of cannabis, in combination with low-doses of alcohol, on a number of outcome measures related to driving. The investigators will focus specifically on the effect of low blood concentrations of THC (0, 125, and 250 µg/kg) alone and in combination with low blood concentrations of alcohol (BAC 0%, .025%, and .049%). They shall determine the combined effect of THC and alcohol on physiological, cognitive, subjective measures of impairment, and simulated driving. This study will focus on younger adults because they have higher impaired driving rates than other age groups. As a secondary aim of the study, the investigators will examine whether previous driving and drug use history are correlated with driving decisions during the simulated drive and subjective measures. This study will contribute to the evidence base informing legislation, policy making, and law enforcement. This study is particularly timely given upcoming changes in legislation about cannabis, and because the combination of THC and alcohol, even below legal thresholds, may lead to impaired driving and crashes.

NCT ID: NCT03467620 Withdrawn - Crohn Disease Clinical Trials

Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease

Start date: July 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To date, few studies have assessed the efficacy and safety of Cannabinoids, compounds derived from the Cannabis plant, in patients with Crohn's disease. Our study seeks to pilot a randomized, placebo-controlled trial assessing the efficacy and safety of oral cannabinoids as an adjunct therapy in patients with Crohn's disease.

NCT ID: NCT03245658 Withdrawn - Mortality Clinical Trials

The Effect of Cannabis in Pancreatic Cancer

Start date: October 6, 2017
Phase: Phase 2
Study type: Interventional

Cannabinoids are known to increase appetite, but THC components have psychogenic properties too. CBD is the main component in the plant, and have only minimal psychogenic effects. The aim was to test the appetite stimulating effects of CBD in patients with pancreatic cancer in palliative treatment.